Clinical Trial Update: Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis [Phase 3]

View source ↗

Summary

Pfizer is evaluating oral tofacitinib in a Phase 3 trial for children aged 2 to 17 with moderate to severe ulcerative colitis; the study is currently active but…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• XELJANZ (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Ulcerative Colitis | Phase 3 | Status: ACTIVE_NOT_RECRUITING